These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046 [TBL] [Abstract][Full Text] [Related]
4. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. Powers V; Ward J; Gompels M HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190 [TBL] [Abstract][Full Text] [Related]
5. CYP2B6-G516T genotype influences plasma efavirenz concentration in a Hong Kong population, allowing potential individualization of therapy. Naftalin CM; Chan KC; Wong KH; Cheung SW; Chan RC; Lee SS HIV Med; 2014 Jan; 15(1):63-4. PubMed ID: 24299220 [No Abstract] [Full Text] [Related]
6. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465 [TBL] [Abstract][Full Text] [Related]
7. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190 [TBL] [Abstract][Full Text] [Related]
8. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522 [TBL] [Abstract][Full Text] [Related]
9. Efavirenz intoxication due to slow hepatic metabolism. Hasse B; Günthard HF; Bleiber G; Krause M Clin Infect Dis; 2005 Feb; 40(3):e22-3. PubMed ID: 15668854 [TBL] [Abstract][Full Text] [Related]
11. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. Ramachandran G; Ramesh K; Hemanth Kumar AK; Jagan I; Vasantha M; Padmapriyadarsini C; Narendran G; Rajasekaran S; Swaminathan S J Antimicrob Chemother; 2009 Apr; 63(4):841-3. PubMed ID: 19218571 [No Abstract] [Full Text] [Related]
12. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Tsuchiya K; Gatanaga H; Tachikawa N; Teruya K; Kikuchi Y; Yoshino M; Kuwahara T; Shirasaka T; Kimura S; Oka S Biochem Biophys Res Commun; 2004 Jul; 319(4):1322-6. PubMed ID: 15194512 [TBL] [Abstract][Full Text] [Related]
13. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Burger D; van der Heiden I; la Porte C; van der Ende M; Groeneveld P; Richter C; Koopmans P; Kroon F; Sprenger H; Lindemans J; Schenk P; van Schaik R Br J Clin Pharmacol; 2006 Feb; 61(2):148-54. PubMed ID: 16433869 [TBL] [Abstract][Full Text] [Related]
14. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671 [TBL] [Abstract][Full Text] [Related]
15. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E Clin Pharmacol Ther; 2010 Nov; 88(5):676-84. PubMed ID: 20881953 [TBL] [Abstract][Full Text] [Related]
16. Clinical impact of patient population differences and genomic variation in efavirenz therapy. King J; Aberg JA AIDS; 2008 Sep; 22(14):1709-17. PubMed ID: 18753940 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. To KW; Liu ST; Cheung SW; Chan DP; Chan RC; Lee SS Ther Drug Monit; 2009 Aug; 31(4):527-30. PubMed ID: 19531981 [TBL] [Abstract][Full Text] [Related]
19. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. Saitoh A; Fletcher CV; Brundage R; Alvero C; Fenton T; Hsia K; Spector SA J Acquir Immune Defic Syndr; 2007 Jul; 45(3):280-5. PubMed ID: 17356468 [TBL] [Abstract][Full Text] [Related]